NNC0268-0965

Framework provides recommendations for effective CKM use for those at risk of diabetic ketoacidosis NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announced the publication of a paper in the journal The Lancet Diabetes & Endocrinology that provides the first international consensus framework for the use of continuous ketone monitoring (CKM) in individuals with diabetes. The paper, "Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology", was authored by an international team of experts in the diabetes field, led by Breakthrough T1D Chief Medical Officer, Thomas Danne, M.D., Dr. Ketan Dhatariya, Consultant in Diabetes and Endocrinology at Norfolk and Norwich University Hospitals and Honorary Professor of Medicine at the University of East Anglia, and Dr. Richard Bergenstal, Executive Director of the International Diabetes Center, HealthPartners Institute. The paper serves as a set of standardized guidelines that healthcare professionals and the entire T1D community can follow as CKM technology becomes available and integrated into broader diabetes care. Individuals with diabetes can face a life-threatening condition called diabetic ketoacidosis (DKA), which occurs when the body breaks down stored fat for energy, generally due to a lack of insulin. This causes ketones to accumulate in the blood, which then becomes acidic, and can lead to death. DKA can occur at any time, often in conjunction with illnesses such as the flu. While ketones can be detected using blood and urine strips, these tools are not widely used, it is difficult to predict when ketone levels may be rising, and the incidence of DKA remains significant. Similar to continuous glucose monitors, CKMs will continuously measure ketones in the body and signal if they are rising. This can help identify and prevent DKA before it occurs and assist individuals in managing their diabetes and insulin therapy safely. "Continuous ketone monitoring has the potential to be a transformational new technology and tool for those living with diabetes and at risk of the life-threatening complication, diabetic ketoacidosis. The new continuous ketone monitoring guidance will play a critical role in ensuring the entire diabetes community is ready to effectively use the technology, once it is available, to improve health outcomes," said Breakthrough T1D Chief Medical Officer Thomas Danne, M.D. "Breakthrough T1D is grateful to all who were on the consensus panel who provided their expertise and came together to develop practical and actionable recommendations that will advance the field and improve diabetes care for all who face the condition." Breakthrough T1D convened and led 33 international experts in the field from 14 countries to develop the consensus guidance, which includes recommendations on common terminology for describing ketone levels, visual device elements that should accompany rates of ketone change, alarm thresholds and triggers, ketone education, and more. This consensus effort aligns with Breakthrough T1D's mission priorities and medical affairs goal of accelerating clinical adoption of new treatments and therapies for T1D. About Breakthrough T1D (formerly JDRF) As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. About type 1 diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. Contact: Casey Fielder 509-651-0087 [email protected] SOURCE Breakthrough T1D, Formerly JDRF 21% more press release views with Request a Demo

New recommendations on technology, obesity medications, and nutrition ARLINGTON, Va., Dec. 8, 2025 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the "Standards of Care in Diabetes—2026" (Standards of Care), the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes. Based on the latest scientific research and clinical trials, the Standards of Care includes strategies for diagnosing and treating diabetes in children, adolescents, and adults; methods to prevent or delay diabetes and its associated comorbidities like obesity; and care recommendations to enhance health outcomes. Continue Reading The gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes. "The 2026 'Standards of Care in Diabetes' represents significant advancement in the delivery of evidence-based, person-centered care. These guidelines synthesize the latest scientific research with practical clinical strategies, thereby equipping health care professionals with the tools necessary to provide optimal care for individuals living with diabetes," said Rita Kalyani, MD, MHS, the ADA's chief scientific and medical officer. Notable updates to the 2026 Standards of Care include: Diabetes technology Recommended use of continuous glucose monitoring at diabetes onset and anytime thereafter to improve outcomes for anyone who could benefit from its use in diabetes management New guidance removing the need to meet certain treatment requirements before initiation of continuous subcutaneous insulin infusion or automated insulin delivery Glucose-lowering medications New guidance on obesity pharmacotherapy dose individualization in people with diabetes New guidance on the treatment of obesity in people with type 1 diabetes New guidance on glucose-lowering therapies in people with chronic kidney disease, including use by those on dialysis Additional guidance on the use of glucose-lowering therapy beyond obesity and glycemic treatment, including heart, kidney, and liver health benefits Nutrition Guidance on the eating patterns with evidence for preventing type 2 diabetes, including Mediterranean-style and low-carbohydrate eating patterns Emphasis on monitoring for adequate nutritional intake and expanded discussion on the importance of physical activity during obesity treatment Diabetes management New guidance for glycemic management for individuals during cancer treatment and for those undergoing organ transplantation Updated blood pressure goals for individuals with high cardiovascular or kidney health risk and for older adults, with a tighter blood pressure goal for those at risk and a more relaxed goal for most older adults Expanded guidance on screening and monitoring individuals at risk for type 1 diabetes, including the utilization of diabetes technology The ADA annually updates its Standards of Care through the efforts of its Professional Practice Committee (PPC) for Diabetes. This year the PPC was co-chaired by Mandeep Bajaj, MBBS, FRCP and Rozalina G. McCoy, MD, MS. Comprising global experts from diverse professional backgrounds, the PPC includes physicians, nurse practitioners, certified diabetes care and education specialists, registered dietitian nutritionists, pharmacists, and methodologists. The committee holds expertise in a range of related fields. The 2026 Standards of Care has garnered endorsements from the following organizations: American Society for Bone and Mineral Research (Bone Health, Section 4) The Obesity Society (Section 8) American College of Cardiology (Section 10) National Kidney Foundation (Section 11) American Geriatrics Society (Section 13) International Society for Pediatric and Adolescent Diabetes (Section 14) Other noteworthy changes include: Guidance on behavioral health screening and referral for concerns such as diabetes distress and anxiety Information on supporting diabetes technology use for children, adolescents, and adults in educational and workplace settings New and updated algorithms on insulin therapy in type 1 diabetes, prevention and treatment of symptomatic heart failure, and chronic kidney disease treatment and atherosclerotic cardiovascular disease prevention in people with type 2 diabetes New discussion on emerging technologies in foot care and information on adjunctive advanced therapies for diabetic foot ulcers Updated guidance for older adults, including continuous glucose monitoring use, protein intake, and assessing geriatric syndromes and functional impairments Updated guidance for children and adolescents, including nutrition education and screening for psychosocial concerns and complications associated with type 1 and type 2 diabetes Updated information on preconception counseling and appropriate non-insulin glucose-lowering therapy discontinuation New hospital guidance, including glycemic goals in the perioperative period and expanded discussion on technology use "The Standards of Care is a vital part of the ADA's efforts to improve the lives of all people affected by diabetes. It offers the trusted support needed for people living with diabetes and those caring for them while we continue to push toward a cure," said Charles "Chuck" Henderson, the ADA's chief executive officer. The 2026 Standards of Care is now available online as a supplement to the January 2026 issue of Diabetes Care®. In addition, a convenient Standards of Care app, available for iOS and Android systems, offers the latest guidelines with interactive tables and algorithms for easy reference. Additional resources, including a comprehensive slide deck and a webcast offering CE credit, are available on the ADA's professional website, DiabetesPro®. A quick-reference pocket chart will soon be available for purchase on ShopDiabetes.org. For primary care professionals, the Abridged Standards of Care, developed by the ADA's Primary Care Advisory Group, is planned for release in spring 2026 in Diabetes, Obesity, and Cardiometabolic CARE®. Through the "living" Standards of Care process, the online version, abridged guidelines, and all related materials will be updated in real time throughout the year to reflect the latest evidence and regulatory changes. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure diabetes—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Contact: [email protected] SOURCE American Diabetes Association 21% more press release views with Request a Demo